Mendez v. Shah, 94 F. Supp. 3d 633

Background

Plaintiff sued Medtronic (multiple corporate defendants) over injuries allegedly caused by the Infuse/Capstone spinal devices; complaint asserted product-liability and breach-of-express-warranty claims.
The Infuse device is a Class III medical device that received FDA premarket approval (PMA); the MDA preemption framework is central to the dispute.
The court previously dismissed several counts and allowed plaintiff to replead manufacturing-defect, failure-to-warn, and express-warranty claims with more detail; plaintiff filed a third amended complaint.
Medtronic moved to dismiss the third amended complaint under Fed. R. Civ. P. 12(b)(6); the court applied Twombly/Iqbal pleading standards and New Jersey substantive law (diversity jurisdiction).
Plaintiff alleged violations of FDA Current Good Manufacturing Practices (CGMP), off-label promotion and misleading publications, aggressive marketing (kickbacks), and that physicians relied on Medtronic materials; she did not identify specific federal regulations paralleling her state claims or specific warranties made to her.
The court dismissed Count IV (PLA manufacturing defect and failure to warn) and Count V (breach of express warranty) as inadequately pleaded and, for failure-to-warn/packaging claims, as preempted where FDA-approved labeling controlled.

Issues

Issue	Plaintiff's Argument	Defendant's Argument	Held
Whether PLA manufacturing-defect and failure-to-warn claims survive despite federal preemption	Mendez alleges CGMP violations and inadequate warnings/packaging for Infuse, asserting those federal standards parallel state-law duties	Medtronic argues MDA preempts state requirements that differ from federal requirements; CGMPs are not a proper parallel or are too general	Dismissed: plaintiff failed to identify specific federal requirements that parallel NJ law; many labeling/packaging claims preempted because FDA approved warnings/packaging
Whether CGMPs can serve as parallel federal requirements to avoid preemption	Plaintiff invokes CGMP violations (misbranding/adulteration) as parallel federal law	Medtronic contends CGMPs are too generic to create enforceable parallel requirements	Court adopts Seventh Circuit reasoning (Bausch): CGMPs can be binding; but plaintiff still failed to plead specific CGMP provisions that parallel her state claims, so dismissal required
Whether breach of express warranty was sufficiently pleaded	Plaintiff alleges Medtronic made express warranties via marketing, studies, articles, and salesperson statements that downplayed risks; physician relied on those representations	Medtronic contends plaintiff did not identify any specific affirmative warranties made to her or relied upon by her physician; statements were general or to the medical community	Dismissed: plaintiff did not allege specific false affirmations that formed the basis of the bargain or identify particular statements relied upon by plaintiff or her doctor
Whether off-label promotion/publications/physician relationships sustain claims	Plaintiff points to allegedly misleading articles, company collaboration with physician-authors, and in-OR promotion as evidence of misrepresentations and warranty/breach	Medtronic asserts public articles and physician-targeted materials are not shown to have been relied upon by plaintiff; labeling approved by FDA limits state-law requirements	Court found plaintiff failed to identify particular false statements or show they became basis of bargain; publications alone insufficient to state express-warranty claim

Key Cases Cited

Riegel v. Medtronic, Inc., 552 U.S. 312 (preemption of state requirements that are different from or in addition to federal device requirements)
Bell Atlantic v. Twombly, 550 U.S. 544 (factual plausibility pleading standard)
Ashcroft v. Iqbal, 556 U.S. 662 (application of Twombly to dismiss conclusory allegations)
Chemical Leaman Tank Lines, Inc. v. Aetna Cas. & Sur. Co., 89 F.3d 976 (3d Cir.) (federal courts in diversity apply forum state substantive law)
Myrlak v. Port Authority of N.Y. & N.J., 157 N.J. 84 (N.J.) (plaintiff may prove manufacturing defect by circumstantial evidence and need not identify specific defect)
Bausch v. Stryker Corp., 630 F.3d 546 (7th Cir.) (CGMPs and FDA quality-system regulations can constitute federal requirements for preemption analysis)
Evancho v. Fisher, 423 F.3d 347 (3d Cir.) (pleading standards and acceptance of well-pleaded facts)
Fowler v. UPMC Shadyside, 578 F.3d 203 (3d Cir.) (Twombly/Iqbal application in Third Circuit)